Drug
VIB7734
VIB7734 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 66.7%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_2
1
33%
Ph phase_1
2
67%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
completed267%
terminated133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_1
A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
NCT03817424
completedphase_2
Study of VIB7734 for the Treatment of Moderate to Severely Active SLE
NCT04925934
terminatedphase_1
Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection
NCT04526912
Clinical Trials (3)
Showing 3 of 3 trials
NCT03817424Phase 1
A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
NCT04925934Phase 2
Study of VIB7734 for the Treatment of Moderate to Severely Active SLE
NCT04526912Phase 1
Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3